Table 7 Relationship between mutation of KRAS gene in exon E3 and clinical parameters
|  | Clinical parameters | No. | KRAS-E3 | Positive rate (%) | χ2 | p value | |
|---|---|---|---|---|---|---|---|
Wild type | Mutant type | ||||||
Age | ≤60 | 112 | 85 | 1 | 0.89 | 0.075 | 0.963 |
>60 | 109 | 81 | 1 | 0.92 | |||
Gender | Male | 114 | 87 | 1 | 0.88 | 0.183 | 0.913 |
Female | 107 | 79 | 1 | 0.93 | |||
Sample type | Tissue sample | 194 | 140 | 2 | 1.03 | 7.436 | 0.115 |
Whole blood sample | 22 | 21 | 0 | 0 | |||
Whole blood + tissue sample | 5 | 5 | 0 | 0 | |||
Pathological type | Squamous cell carcinoma | 15 | 12 | 0 | 0 | 3.399 | 0.757 |
Adenocarcinoma | 155 | 113 | 1 | 0.65 | |||
Adenosquamous carcinoma | 7 | 5 | 0 | 0 | |||
Staging | Stage IA | 22 | 15 | 1 | 4.55 | 9.357 | 0.808 |
Stage IB | 51 | 38 | 0 | 0 | |||
Stage IIA | 8 | 6 | 0 | 0 | |||
Stage IIB | 9 | 8 | 0 | 0 | |||
Stage IIIA | 23 | 16 | 0 | 0 | |||
Stage IIIB | 5 | 4 | 0 | 0 | |||
Stage IV | 33 | 29 | 0 | 0 | |||
Treatment | Surgery | 67 | 51 | 1 | 1.49 | 2.612 | 0.856 |
Chemotherapy | 37 | 26 | 0 | 0 | |||
Surgery + chemotherapy | 66 | 51 | 0 | 0 | |||